A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme is a PHASE1 clinical asset sponsored by Beijing Sanbo Brain Hospital in Glioblastoma Multiforme. SEO and diligence focus: Anti-PD-L1 CSR T cells, Cyclophosphamide, Fludarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.